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To detect as yet unidentified cell-surface molecules specific to hematopoietic stem cells 
(HSCs), a modified signal sequence trap was successfully applied to mouse bone marrow 
(BM) CD34
 
 
 
c-Kit
 
 
 
Sca-1
 
 
 
Lin
 
 
 
 (CD34
 
 
 
KSL) HSCs. One of the identified molecules, Endomucin, 
is an endothelial sialomucin closely related to CD34. High-level expression of Endomucin 
was confined to the BM KSL HSCs and progenitor cells, and, importantly, long-term 
repopulating (LTR)–HSCs were exclusively present in the Endomucin
 
 
 
CD34
 
 
 
KSL population. 
Notably, in the yolk sac, Endomucin expression separated multipotential hematopoietic cells 
from committed erythroid progenitors in the cell fraction positive for CD41, an early 
embryonic hematopoietic marker. Furthermore, developing HSCs in the intraembryonic 
aorta-gonad-mesonephros (AGM) region were highly enriched in the CD45
 
 
 
CD41
 
 
 
Endomucin
 
 
 
 
fraction at day 10.5 of gestation (E10.5) and in the CD45
 
 
 
CD41
 
 
 
Endomucin
 
 
 
 fraction at 
E11.5. Detailed analyses of these fractions uncovered drastic changes in their BM 
repopulating capacities as well as in vitro cytokine responsiveness within this narrow time 
frame. Our findings establish Endomucin as a novel cell-surface marker for LTR-HSCs 
throughout development and provide a powerful tool in understanding HSC ontogeny.
 
Hematopoietic stem cells (HSCs) are defined
as cells that retain the capacities for both self-
renewal and multilineage differentiation. We
have previously reported that in adult mouse
BM, CD34
 
low/
 
 
 
c-Kit
 
 
 
Sca-1
 
 
 
Lin
 
 
 
 (CD34
 
 
 
KSL)
cells, which constitute 
 
 
 
0.004% of BM cells,
represent HSCs with long-term repopulating
(LTR) ability, whereas CD34
 
 
 
KSL cells are
progenitors with short-term repopulating capac-
ity (1). In adult mice, HSCs reside in the so-
called “stem-cell niche,” which forms the
microenvironment for HSCs in the BM. HSC
behaviors are regulated by signals from their
niche through cell-surface or secreted molecules.
Understanding the molecular mechanisms un-
derlying these cell–cell interactions holds the
key for HSC biology and is of biological and
clinical interest. Moreover, identification of
cell-surface molecules on HSCs is also impor-
tant to obtain a truly specific marker for HSCs.
However, experiments with HSCs have been
hampered by the very low rate at which HSCs
are found in BM, leaving their molecular nature
unknown. Recent technological innovation is
overcoming this hurdle, and extensive gene
expression profiling is providing a list of genes
potentially involved in HSC function (2–4).
Yet the list of cell-surface molecules whose
presence is currently used to mark HSCs is
short; in addition, many of these molecules also
are expressed by certain cells that bear lineage-
differentiation markers (5, 6). For this reason,
most approaches to HSC purification still include
selection by the absence of certain molecules,
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such as lineage markers, CD34, and Flk2/Flt3 (1, 7, 8).
Even selection for dye efflux activity (9) is a selection by
negative criterion.
Two waves of hematopoiesis occur in the mouse em-
bryo. The first transient wave of primitive hematopoiesis is
characterized by the presence of nucleated red cells express-
ing embryonic globin 
 
 
 
H
 
1
 
 and is detected in the yolk sac as
early as day 7.5 (E7.5) of gestation (10). Definitive hemato-
poiesis that supplies adult-type red blood cells arises as the
second wave in the E10.5 intraembryonic aorta-gonad-
mesonephros (AGM) (11, 12). CD41 is known to mark
the initiation of primitive and definitive hematopoiesis in
the embryo, although its expression is down-regulated in
hematopoietic progenitors by the fetal liver stage (13–15).
In the AGM region, all adult-engrafting cells derived from
the E10.5 to E12.5 AGM region reportedly express tran-
scription factor Runx1 and, interestingly, adult-engrafting
cells change their profile from CD45
 
 
 
 to CD45
 
 
 
 between
E10.5 and E11.5 (16). Two markers for adult HSCs, c-Kit
and CD34, are also expressed on adult-engrafting cells in the
AGM region and fetal liver (17). Despite extensive experi-
ments that have defined the temporal and anatomical differ-
ences between primitive and definitive hematopoiesis, little
is known about the development of HSCs in the embryo,
and markers for developing HSCs are limited.
To identify novel cell-surface molecules on HSCs, we
combined long-distance PCR amplification of full-length
cDNA from purified HSCs with a signal sequence trap by
retrovirus-mediated expression screening (SST-REX) (18).
With this method, we identified several genes encoding
cell-surface or secreted proteins preferentially expressed by
mouse BM CD34
 
 
 
KSL HSCs. One of these genes, 
 
Endomu-
cin
 
, has been shown to encode an endothelial sialomucin
closely related to CD34 (19, 20). In this study, we show that
Endomucin is preferentially expressed on both LTR-HSCs
in adult BM and developing HSCs in the embryo. Of im-
portance is that Endomucin expression in the embryo was
specific to adult-engrafting HSCs and multipotential progen-
itors and was not detected on committed erythroid progeni-
tor cells of both primitive and definitive types. Using Endo-
mucin as a novel positive HSC marker, we present our
success in tracing HSCs throughout development and define
Endomucin as a new tool useful in understanding the ontog-
eny of HSCs.
 
RESULTS
Identification of 
 
Endomucin
 
 as an HSC-specific gene
 
To identify cell-surface molecules specific to HSCs, we took
advantage of an SST-REX cloning method. This method de-
tects signal sequences in cDNA libraries based on the se-
quences’ ability to redirect a constitutively active mutant of
c-Mpl to the cell surface, thereby permitting IL-3–indepen-
dent growth of Ba/F3 cells (18). We successfully applied SST-
REX to a limited number of CD34
 
 
 
KSL HSCs (Fig. 1 A).
From 231 IL-3–independent clones, we isolated 128 cDNAs
and identified 46 genes. Of these, 36 were known murine
genes, 4 were putative murine homologues of human genes,
and 6 were unknown murine genes (Table S1, available at
http://www.jem.org/cgi/content/full/jem.20051325/DC1).
RT-PCR analysis of selected genes revealed that several genes
were preferentially expressed in hematopoietic stem and pro-
genitor fractions (Fig. 1 B). Among these genes, mRNA ex-
pression of 
 
Endomucin
 
 was restricted to CD34
 
 
 
KSL cells. The
extracellular domain of Endomucin is highly glycosylated
with 
 
O
 
-linked glycans (Fig. 1 C) (19). Its structure indicates
membership in a sialomucin family that includes CD34, a
well-characterized molecule specific to hematopoietic and en-
dothelial systems. Endomucin was originally identified as an
endothelium-associated marker (19, 21), but it had not yet
been investigated in hematopoietic lineage cells. We therefore
examined the expression of Endomucin on HSCs.
 
Expression of Endomucin on adult BM HSCs
 
Using anti-Endomucin mAbs, clone V.7C7 (19) and clone
2D4 (newly generated for this study), expression of Endo-
mucin was extensively analyzed in adult hematopoietic cells
of BM, spleen, and thymus. Endomucin was not expressed
Figure 1. SST screening of CD34 KSL cells. (A) Overview of SST cloning. 
Full-length cDNA amplified from 5,000 CD34 KSL cells was digested into 
pieces, ligated with BST-XI adaptor, and subcloned into an SST-REX vector. 
TM, transmembrane domain. (B) Expression of representative clones detected 
by RT-PCR. Genes depicted are Endomucin, CLEC (c-type lectin-like receptor), 
PEDF (pigment epithelium-derived factor), and Serpentine (sequences are 
available from GenBank/EMBL/DDBJ under accession nos. AF060883, 
BC052840, NM_011340, and AF166382, respectively). Cells analyzed 
include BM CD34 KSL HSCs, progenitors, Lin  cells, Gr-1  neutrophils, 
Mac-1  monocytes/macrophages, TER119  erythroblasts, B220  B cells, 
spleen Thy-1.2  T cells, NK1.1  NK cells, B220  B cells, thymic CD4 CD8  
T cells (DN), CD4 CD8  T cells (DP), CD4 CD8  T cells (CD4SP), and CD4  
CD8  (CD8SP). (C) Schematic representation of Endomucin protein. N- and 
O-linked glycosylation in the extracellular domain and the potential protein 
kinase C phosphorylation sites (serine and threonine residues) in the cyto-
plasmic domain are indicated. 
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on a vast majority of cells bearing lineage markers, including
Gr-1–, Mac-1–, B220-, CD4-, CD8- and TER119-positive
cells. Only small populations of BM B220
 
 
 
 (0.66%) and
spleen B220
 
 
 
 cells (1.8%), which appeared to be B220
 
 
 
CD43
 
 
 
IgM
 
 
 
 mature B cells, expressed Endomucin (unpub-
lished data). A fraction of Mac-1
 
low
 
 cells, representing 0.39%
of total BM cells, also expressed Endomucin (unpublished
data). Mac-1 is a surface antigen that is highly expressed
on myeloid cells but also moderately expressed on some
short-term repopulating hematopoietic progenitor cells (22).
These findings showed good correlation with our RT-PCR
data.
By using magnetic cell sorting to deplete Lin
 
 
 
 cells, Lin
 
 
 
BM mononuclear cells were enriched to 85.7 
 
 
 
 4.8% of the
preparations. Lineage-depleted BM cells were segregated into
subpopulations defined by levels of Endomucin expression.
Each subpopulation was tested for expression of c-Kit and
Sca-1. The subpopulation with the highest level of Endomu-
cin expression was enriched for KSL immature hematopoietic
cells (Fig. 2 A). Conversely, 83.4% of KSL cells expressed En-
domucin (Fig. 2 B). These data indicated that Endomucin is
abundantly expressed on immature hematopoietic cells.
To evaluate Endomucin expression on HSCs directly, we
next analyzed Endomucin expression on CD34
 
 
 
KSL cells.
Lineage-depleted BM cells were further analyzed for the ex-
pression of CD34, c-Kit, Sca-1, and Endomucin. Most
CD34
 
 
 
KSL cells (71%) strongly expressed Endomucin (Fig.
3 A). Although the expression level of Endomucin on
CD34
 
 
 
KSL cells was relatively low compared with that
on CD34
 
 
 
KSL cells, Endomucin protein persisted on most
CD34
 
 
 
KSL cells (78%). The KSL fraction was then segre-
gated by expression of Endomucin and of CD34, and single
cells from each fraction were sorted into 96 microtiter plates
to allow colony formation. Endomucin
 
 
 
CD34
 
 
 
KSL cells
showed the highest efficiency of colony formation. Moreover,
this fraction was most enriched for CFU-neutrophil/mac-
rophage/erythroblast/megakaryocyte that retained multilin-
eage differentiation capacity (Fig. 3 A). To determine whether
Endomucin expression identifies cells with LTR capacity, we
transplanted cells from each fraction into lethally irradiated
mice (Fig. 3 C). 6 mo after transplantation, long-term repopu-
lation was detected only with Endomucin
 
 
 
CD34
 
 
 
KSL cells
but not with Endomucin
 
 
 
CD34
 
 
 
KSL cells. These data clearly
show that all LTR-HSCs express Endomucin.
The engraftment rate of Endomucin
 
 
 
CD34
 
–
 
KSL cells
(8/18 recipient mice) was lower than that which we have
previously reported for CD34
 
–
 
KSL cells (1, 23). We ascribe
this to incomplete depletion of Lin
 
 
 
 cells. To include an
anti-Endomucin antibody in four-color FACS analysis and
cell sorting, Lin
 
 
 
 cells were depleted only by using magnetic
beads, and the remaining Lin
 
 
 
 cells were not gated out on
FACS cell sorting. This appears to have lowered the purity
of HSCs in this population. To exclude the possibility that
anti-Endomucin antibody inhibits HSC homing in vivo, we
transplanted HSCs preincubated with anti-Endomucin anti-
body. However, it did not affect the engraftment rate (un-
published data).
Knowing that Endomucin expression marks all HSCs
and correlates well with c-Kit and Sca-1 expression, we next
investigated whether Endomucin, as a marker, could replace
c-Kit and Sca-1. In competitive repopulation assays, again
only Endomucin
 
 
 
CD34
 
 
 
Lin
 
 
 
 cells contributed to long-
term repopulation. As few as 100 cells were enough to ob-
tain a higher order of repopulation (Fig. 3, B and C), indi-
cating that the single marker Endomucin could substitute for
c-Kit and Sca-1 to a large extent.
 
Erythroid progenitors are devoid of Endomucin expression 
in the yolk sac
 
We next asked whether Endomucin is expressed on hemato-
poietic cells of the developing embryo. In mouse embryos,
blood cells first appear in the extraembryonic yolk sac (10).
Consistent with other experiments, colony-forming cells
(CFCs) in methylcellulose medium were present only in the
yolk sac at E8.5. Most CFCs were confirmed as primitive
erythroid progenitor (Ery
 
P
 
) cells by identification of unique
morphologic features and of expression of 
 
 
 
H
 
1
 
 embryonic
hemoglobin specific to primitive hematopoiesis (unpub-
lished data). Endomucin expression was then analyzed in
Figure 2. Endomucin expression on BM hematopoietic cells. (A) Level 
of Endomucin expression correlates with immature cell phenotype. Lin  
BM cells were divided into five subgroups (i–v) defined by Endomucin 
expression levels (top left). Each group was further analyzed with respect 
to expression of c-Kit and Sca-1. Panel numbers correspond to each 
subgroup. The percentage of c-Kit Sca-1  cells is indicated in panel v. 
(B) Endomucin expression in KSL cells. Expression of Endomucin in the KSL 
cell fraction (left, inset) is presented (right). KSL cells were stained with an 
isotype control IgG (continuous line) and the anti-Endomucin antibody 
(dashed line). The percentage of Endomucin  cells is indicated. 
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correlation with CD41, one of the most reliable markers for
embryonic hematopoietic progenitor cells (13, 14), and with
CD45, a panhematopoietic marker. In the yolk sac at E8.5,
methylcellulose colony assays demonstrated that CFCs, in-
cluding Ery
 
P
 
-CFCs, are present only in the Endomucin
 
 
 
fraction irrespective of cellular expression of CD41 or CD45
(Fig. 4, A and B). In the yolk sac at E10.5, again, erythroid
progenitor cells of a definitive type, including CFU-E and
BFU-E, were observed only in the Endomucin
 
 
 
 fraction in
methylcellulose culture medium. In contrast, Endomucin
 
 
 
cells gave rise exclusively to mixed colonies, which consisted
mostly of macrophages and erythroid cells, although their
origin (i.e., in primitive or definitive hematopoiesis) remains
obscure (Fig. 4, C and D). These data indicate that Endomu-
cin is not expressed on erythroid progenitor cells of either
primitive or definitive type but is expressed on multipotent
progenitor cells that develop in the yolk sac.
Endomucin expression marks HSCs in the embryo
It is reported that the E10.5 AGM autonomously produces
HSCs that repopulate hematopoiesis in adults (11, 12). In a
previous immunohistochemical analysis, specific Endomucin
expression was observed at E8.5 to E11.5 on the endothe-
lium of the dorsal aorta and in cell clusters associated with
the luminal surface of the endothelium (24). These findings
indicate tight correlation of Endomucin expression with HSC
development and prompted us to analyze AGM hemato-
poiesis at E10.5 to E11.5.
In contrast with the findings in the E10.5 yolk sac (Fig. 4
D), the vast majority of hematopoietic activity in the E10.5
AGM was detected within CD45  cells (Fig. 5, A and D).
FACS analysis demonstrated that  0.16% of CD45  cells
were CD41 Endomucin  and that Endomucin expression
was restricted to a population of CD41dim cells (Fig. 5 A).
Among CD45  cells, those which were CD41 Endo-
mucin  composed the main population that gave rise to col-
onies in methylcellulose medium (Fig. 5 D). Co-culture of
early murine AGM cells with stromal cells is reported to fa-
cilitate hematopoiesis from hemangioblasts (25). We used
this co-culture system as well as methylcellulose culture.
Surprisingly, when co-cultured with OP-9 stromal cells,
CD45 CD41 Endomucin  cells showed a plating efficiency
38-fold higher than that in methylcellulose medium and
a plating efficiency 4.6-fold higher than that of CD45 
CD41 Endomucin  cells (Fig. 5 D). This CD45 CD41 
Endomucin  population proliferated extensively (Fig. 5 E)
and differentiated into multiple lineages (unpublished data).
In contrast, CD45 CD41 Endomucin  cells formed VE-
cadherin  endothelial cell colonies on OP-9 cells in the
presence of vascular endothelial growth factor (unpublished
data) but formed no hematopoietic colonies (Fig. 5 D), sug-
gesting that this population includes pure endothelial cells.
Embryonic stem (ES) cell differentiation in vitro recapitu-
lates the embryonic development. We additionally used an
ES cell differentiation model to confirm the correlation of
Endomucin expression with developing HSCs. ES cells were
Figure 3. Endomucin expression on LTR-HSCs. (A) Expression of 
Endomucin on CD34 KSL cells. KSL cells (left, inset) were divided into four 
populations defined by expression of CD34 and of Endomucin (middle). 
The percentage of cells in each population is shown. The colony-forming 
capacity of each gated population is shown (right). 48 single cells from 
each population were sorted clonally into 96-well microtiter plates and 
cultured in the presence of SCF, IL-3, TPO, and EPO for 14 d to allow colony 
formation. Colonies were recovered and morphologically examined to 
determine their composition. (B) Expression of Endomucin on CD34 Lin  
cells. BM Lin  cells were divided into four populations defined by expression 
of CD34 and Endomucin. The percentage of cells in each population is 
shown. (C) Competitive lymphohematopoietic repopulation capacity of 
Endomucin  and Endomucin  subpopulations of CD34 KSL cells and 
CD34 Lin  cells. The indicated number of cells from each subpopulation 
(B6-Ly5.1) and competitor cells from B6-Ly5.1   Ly5.2 F1 mice were 
mixed and injected into lethally irradiated B6-Ly5.2 recipient mice. The 
chimerism percentage of donor cells 6 mo after transplantation is pre-
sented as mean   S.D. Mice that had  1% chimerism in each lineage 
were considered to be multilineage reconstituted (positive mice). nmEM, 
neutrophil/macrophage/erythroblast/megakaryocyte colony.JEM VOL. 202, December 5, 2005 1487
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allowed to differentiate by forming embryoid bodies (EB;
i.e., aggregates containing three germ layers), and their me-
sodermal differentiation was monitored by flow cytometry
up to day 10 (EB10). Endomucin  cells appeared around EB5
(Fig. S1 A, available at http://www.jem.org/cgi/content/
full/jem.20051325/DC1), which is later than the onset of
formation of hemangioblasts (EB3) that give rise to primitive
hematopoiesis. With respect to hematopoiesis, EB4 to EB6
corresponds to the developmental stage around E8.5 to
E10.5 (13). As observed with AGM cells, CD45 CD41 
Endomucin  cells at EB4 to EB6 showed robust expansion
on OP-9 stromal cells (Fig. S1, B and C), whereas CD45 
cells did not proliferate at all (not depicted). These data cor-
relate well with and strongly support the findings in the
AGM (Fig. 5, D and E).
We next analyzed cells from the E11.5 AGM, which re-
portedly exhibit higher hematopoietic activity (17). Interest-
ingly, hematopoietic activity largely shifted to CD45  cells
in the E11.5 AGM (Fig. 5, D and E). Although only 5%
of AGM cells were CD45 , Endomucin expression on
CD41dim cells identified cells with the highest hematopoietic
potential. These CD45 Endomucin  cells notably exhibited
high plating efficiency both in methylcellulose medium and
on OP-9 stromal cells (Fig. 5, D and E).
To define HSC properties of Endomucin  AGM cells,
we directly evaluated the capacity of Endomucin  cells to
repopulate adult BM hematopoiesis in vivo. Fractionated
AGM cells at E10.5 were transplanted directly into the BM
of lethally irradiated adult mice. Although the degree of chi-
merism was low, as few as 750 CD45 CD41 Endomucin 
cells were enough to establish long-term repopulation (Table
I), whereas other fractions did not contribute to long-term
repopulation at all. Additionally, and in keeping with the in
vitro data, LTR-HSCs with enhanced engrafting capacity
were detected only in the CD45 Endomucin  fraction of
Figure 4. Endomucin is not expressed on mouse EryP cells during 
development. FACS profiles of E8.5 (A) and E10.5 (C) yolk sac cells. Sorting 
gates for colony assays are depicted and the percentage of cells in each 
gate is shown. Numbers of CFUs in methylcellulose culture contained in 
indicated E8.5 (B) and E10.5 (D) yolk sac fractions are shown. CFU-M, CFU-
macrophage; CFU-E, CFU-erythroid; CFU-Mix, mixed CFU; BFU-E, burst-
forming unit–erythroid. The results are shown as means   S.D. of triplicate 
cultures.
Figure 5. Endomucin traces the ontogeny of definitive HSCs in AGM. 
(A) FACS profile and sorting gates of E10.5 AGM cells. The percentage of 
CD45  cells in total E10.5 AGM cells is indicated. (B) RT-PCR mRNA expression 
profiles of HSC-affiliated genes in indicated fractions of E10.5 AGM cells. 
(C) FACS profile and sorting gates of CD45  (left) and CD45  (right) E11.5 
AGM cells. The percentage of CD45  and CD45  cells in total E11.5 AGM cells 
are indicated. (D) E10.5 and E11.5 AGM fractions were subjected to methyl-
cellulose culture (MC) and OP-9 co-culture (OP-9) assays. In both assays, cells 
were incubated in the presence of SCF, TPO, IL-3, and EPO for 6–8 d. Plating 
efficiency (percentages of colony numbers against plated cell numbers) is 
presented as mean   S.D. of triplicate cultures. (E) Growth of the E10.5 and 
E11.5 AGM fractions in OP-9 co-culture. Cell numbers at day 6 are presented 
per 104 starting cells as means   SD of triplicate cultures.ENDOMUCIN MARKS HSCS THROUGHOUT DEVELOPMENT | Matsubara et al. 1488
E11.5 AGM cells (Table I). Of interest was that E10.5 AGM
cells preferentially contributed to B cell repopulation, whereas
E11.5 AGM cells established multilineage repopulation
(Table I).
To understand the genetic background of E10.5 AGM
cells, fractionated cells were analyzed on the mRNA ex-
pression of HSC-related genes (Fig. 5 B). CD45 CD41 
Endomucin  cells coexpressed CD34 and c-kit, the cell-
surface marker genes for AGM HSCs (17). In contrast,
CD45 CD41 Endomucin  cells expressed c-kit at a consid-
erably lower level. Relatively high levels of transcription fac-
tors SCL, Runx1, and GATA-2, which are indispensable for
HSC development (16, 26, 27), were detected in CD45 
CD41 Endomucin  cells, whereas GATA-1, which is highly
expressed in erythroid-committed cells (28), was preferen-
tially expressed in CD45 CD41 Endomucin  cells. These
expression profiles strongly support our findings that CD45 
CD41 Endomucin  cells are enriched for developing
HSCs, whereas CD45 CD41 Endomucin  cells are en-
riched for erythroid-committed progenitor cells.
At the developmental stage of E11 to E11.5, HSCs and
progenitor cells could already be detected in the liver, into
which they are presumed to have migrated via the circula-
tion. Fetal liver serves as a major hematopoietic site from
E11 until hematopoiesis is taken over by the BM. To char-
acterize Endomucin  cells in the fetal liver, we next used
c-Kit as a hematopoietic marker because CD41 expression
on primitive hematopoietic cells gradually declines after E11
(14). In the fetal liver, a small population of Lin c-Kithigh
cells appeared to express Endomucin (Fig. S2 A, available at
http://www.jem.org/cgi/content/full/jem.20051325/DC1).
Among these Lin c-kithighEndomucin  cells, Sca-1 expres-
sion was up-regulated between E11.5 and E12.5, and all
CD34 KSL HSCs in E14.5 fetal liver were identified as
Endomucin  (Fig. S2 B).
DISCUSSION
Among several genes identified by SST-REX cloning, Endo-
mucin is noteworthy, as it encodes a protein that belongs to
the sialomucin family. CD34 is the prototypic member of
this family and has been widely used as a marker of HSCs
and/or progenitor cells and of endothelial cells. The highly
conserved amino acid sequence, protein structure, and ge-
nomic organization of CD34, endoglycan, and podocalyxin
suggest that they are closely related to each other (29). These
molecules reportedly are expressed on HSCs and/or progen-
itor cells and on endothelial cells and are supposed to have
redundant functions (29, 30). Although Endomucin exhibits
a protein structure highly related to that of these three mole-
cules, its genomic structure is distant, indicating a different
phylogeny (19).
Endomucin was originally identified as an endothelium-
specific protein (19), but we and others have reported possi-
ble involvement of Endomucin in HSC development in the
embryo (24, 31). Identification of Endomucin on SST-REX
screening of adult BM HSCs thus encouraged us to perform
Table I. Endomucin marks LTR-HSCs in AGM
Percent chimerism for donor cells
Cell type
Cells per 
mouse Engrafted mice Total
Myeloid
cell B cell T cell
E10.5 AGM
45 41 E  750 0/4 - - - -
45 41 E  750 4/4 0.4   0.3 0.11   0.02 1.4   0-
45 41 E  750 0/4 - - - -
45 41 E  750 0/4 - - - -
45  750 0/5 - - - -
E11.5 AGM (Exp.-1)
45 41  3,615 0/5 - - - -
45 41 E  122 0/3 - - - -
45 41 E  172 0/5 - - - -
45 E  112 1/3 17.5 1.72 46.9 6.56
45 E  500 0/5 - - - -
E11.5 AGM (Exp.-2)
Whole 105 2/4 14.9/67.8 0.6/71.9 30.4/67.8 35.1/60.8
45 E  1,829 0/4 - - - -
45 E  4.5   104 0/4 - - - -
45 E  289 1/3 18.3 0.8 27.2 20.4
45 E  6,000 0/4 - - - -
Results of competitive adult BM repopulation assays using E10.5 and E11.5 AGM cells. The indicated number of cells from each subpopulation (B6-Ly5.2) was mixed with 1   
105 B6-Ly5.1 competitor cells. The mixture was injected directly into the BM (intra-BM transplantation) of lethally irradiated B6-Ly5.1 recipient mice. An additional 2   105 B6-
Ly5.1 competitor cells were injected intravenously. E, Endomucin.JEM VOL. 202, December 5, 2005 1489
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thorough studies of the role of Endomucin in the hemato-
poietic system.
In adult BM, Endomucin expression correlated with im-
mature hematopoietic phenotype, and cells with the highest
levels of Endomucin expression were enriched for KSL cells,
a population enriched for HSCs (Fig. 2). Conversely, most
KSL cells, both CD34 KSL HSCs and CD34 KSL progeni-
tor cells, expressed Endomucin. Importantly, LTR-HSCs
were identified only in the Endomucin  subpopulation of
CD34 KSL cells. As Endomucin was identified on  71%
(10% / [10%   4%]) of CD34 KSL cells, to detect its ex-
pression did not largely promote further HSC enrichment of
the CD34 KSL HSC fraction (Fig. 3 A). However, we
demonstrated that, as a marker, Endomucin could substitute
for both c-Kit and Sca-1 to a large extent (Fig. 3 C). In this
regard, Endomucin might be a useful HSC marker for sim-
plifying mouse HSC enrichment. We also have confirmed
that expression of Endomucin is specific to the human HSC
fraction at the mRNA level (unpublished data). This sug-
gests that Endomucin would promote enrichment of human
HSCs as well.
In the developing mouse, hematopoiesis is detected as
early as E7. In this stage, hematopoietic elements consist of
primitive erythroid cells (32). During HSC development in
the embryo, the expression pattern of Endomucin was dis-
tinct from that of CD41 in that Endomucin was not ex-
pressed on EryP cells in the yolk sac. This finding is sup-
ported by the lack of reaction in blood islands of the
extraembryonic yolk sac at E8 when reacted with an anti-
Endomucin antibody (24). On the other hand, Endomucin
expression was demonstrated on all LTR-HSCs in the AGM
(Table I). After a transient wave of primitive hematopoiesis
in the yolk sac, LTR-HSCs capable of engrafting adult mice
emerge in the AGM at E10.5 (11, 12). These LTR-HSCs
reportedly do not express CD45 (16, 33). Consistent with
these studies, HSC activity was confined to the CD45  frac-
tion and only CD41 Endomucin  cells retained substantial
LTR activity in adult irradiated recipient mice, although the
degree of chimerism established was rather low, as previously
reported (16, 33, 34). CD45 CD41 Endomucin  cells
formed scarcely any hematopoietic colonies in methylcellu-
lose medium but exhibited a strikingly high plating effi-
ciency of  23% and generated multilineage hematopoietic
cells when co-cultured with stromal cells (Fig. 5, D and
E). From these findings, we suggest that CD45 CD41 
Endomucin  cells in E10.5 AGM are enriched for the earli-
est HSC and progenitor cells, which require further matura-
tion both to attain an engrafting capacity equivalent to that
of adult HSCs and to respond to conventional mitogenic cy-
tokines in vitro. This unique property of Endomucin  AGM
cells in vitro was also observed in similar cells obtained from
the yolk sac at E10.5 (Fig. 4 D and not depicted), suggest-
ing that Endomucin marks developing HSCs and progeni-
tor cells not only in the AGM but also in the yolk sac. In-
triguingly, HSC activity in the AGM largely shifted to
CD45 CD41 Endomucin  cells by E11.5; this subpopula-
tion also exhibited high proliferative capacity both in vitro
and in vivo (Fig. 5, D and E, and Table I).
In summarizing our data and their implications, we pro-
pose that HSCs initially branch from putative hemogenic
endothelium as CD45 CD41 Endomucin  cells with lim-
ited repopulation capacity in vivo. These immature HSCs,
or “developing HSCs,” undergo a maturation process and
become CD45  “definitive HSCs” with nearly complete
engrafting capacity in adult recipient mice as well as multi-
lineage repopulation capacity (Fig. 6). In AGM, Endomucin
is highly expressed on the endothelium of the dorsal aorta,
on budding cells from the endothelium, and on cell clusters
associated with the luminal surface of the endothelium (24).
In contrast, CD41 expression is restricted to budding cells
and to hematopoietic clusters (15, 33, 35). These immuno-
histological findings further indicate that in the E10.5 AGM,
CD45 CD41 Endomucin  cells may represent budding HSCs
arising from the hemogenic endothelium of the dorsal aorta;
these then mature into CD45 CD41 Endomucin -defini-
tive HSCs in the E11.5 AGM.
Injection of HSCs into BM has considerably improved
the engrafting capacity of human CD34  HSCs and human
ES-derived HSCs in adult recipient mice. This technique
supposedly overcomes both defects in human CD34  HSCs
homing to recipient mouse BM and intravenous aggregation
of human ES-derived HSCs (36, 37). Because AGM cells,
particularly E10.5 AGM cells, reportedly are scarcely capable
of engrafting adult recipients, we expected that intra-BM in-
jection would improve engraftment. As expected, engraft-
Figure 6. Endomucin and developing HSCs. A model for developing HSCs 
in the embryo. In the AGM, hematopoietic cells of definitive type appear in the 
CD41  population. At around E10.5, the first HSCs to emerge (developing 
HSCs) can be identified by the phenotype CD45 CD41 Endomucin . By 
E11.5, they mature to CD45 CD41 Endomucin  HSCs (definitive HSCs) 
that retain multilineage repopulation capacity in adult irradiated mice. 
Shaded boxes indicate cells with CD45  phenotype.ENDOMUCIN MARKS HSCS THROUGHOUT DEVELOPMENT | Matsubara et al. 1490
ment by E10.5 AGM cells was observed using this method.
Its efficacy in embryonic HSC transplantation, however,
needs further evaluation, including direct comparison with
intravenous injection and transplantation into busulfan-
treated newborn mice or immunodeficient recipients.
Although controversy persists, cells originating from
both the yolk sac and AGM are supposed to seed the fetal
liver, where they acquire the capacity to engraft and to re-
constitute the BM (38, 39). We and others have previously
reported that HSCs repopulating adult recipient mice are
first detectable in the fetal liver at E11.5 to E12 and mark-
edly expand in number by E12.5 (34, 40). Focusing on
Lin c-KithighEndomucin  cells in the fetal liver, we ob-
served a drastic up-regulation of Sca-1 expression at E12.5
(Fig. S2 A). The phenotypic change in Sca-1 expression on
Lin c-KithighEndomucin  cells may track the maturation
process of embryonic HSCs as they acquire a higher capacity
to engraft the adult BM niche.
Even though the function of Endomucin in HSCs is un-
known, impaired BM engraftment of CD34-deficient BM
cells recently has been demonstrated. This impairment was
attributed in part to antiadhesive activity on the part of
CD34 (41). It is intriguing that CD34 homologues and En-
domucin also have antiadhesive activity (31, 41–43). In this
regard, antiadhesive activity of Endomucin may also play a
role in HSC behavior in vivo.
Finally, our findings establish Endomucin as a novel LTR-
HSC marker from their developing stage onward, and will
provide a powerful tool in understanding HSC ontogeny.
MATERIALS AND METHODS
Mice. C57BL/6-Ly5.2 mice were purchased from SLC. C57BL/6-Ly5.1
mice and Ly5.1   Ly5.2 F1 mice were bred and maintained in the Animal
Research Facility of the Institute of Medical Science at the University of
Tokyo. All experiments using mice received approval from the University
of Tokyo Administrative Panel for Animal Care.
Signal sequence trap cloning. SST-REX cloning (18) was performed
with partial modification. 5,000 CD34 KSL cells were obtained by cell sort-
ing, and total RNA was extracted using ISOGEN reagent (Nippon Gene).
cDNA was synthesized using a PCR cDNA synthesis kit (SMART; CLON-
TECH Laboratories, Inc.) and oligo-dT primer. cDNA was digested with RsaI
restriction enzyme and linked with a BstXI adaptor. cDNA fragments ranging
from 0.5 to 2.0 kb were size selected by electrophoresis on a 1% agarose gel
and subcloned into a pMX-SST vector. An SST-REX library (2   106 inde-
pendent clones) was subjected to screening as previously described (18).
RT-PCR. Semiquantitative RT-PCR was performed using normalized
cDNA and quantitative PCR, with rodent GAPDH control reagent (Taq-
Man; Perkin-Elmer Applied Biosystems) as previously described (44). The
primer sequences are as follows: Endomucin sense, 5 -ACAACTGAAG-
GTCCCCTAAGG-3 , and antisense, 5 -TTGGTTTTCCCCTGTGCA-
GAC-3 ; CD34 sense, 5 -TCCTGATGAACCGTCGCAGTTG-3 , and
antisense, 5 -TGTCAGCCACCACATGTTGTC-3 ;  c-Kit sense, 5 -
CTGGACCTGGATGATTTGCT-3 , and antisense, 5 -GAGCTCCCA-
GAGGAAAATCC-3 ; GATA-1 sense, 5 -AAAGATGGAATCCAGAC-
GAGG-3 , and antisense, 5 -GTCAAGGCTATTCTGTGTACC-3 ;
GATA-2 sense, 5 -AGTGCATGCAAGAGAAGTCAC-3 , and antisense,
5 -ATGGCAGTCACCATGCTGGAC-3 ; SCL sense, 5 -GAACGATG-
GAGGCAGCAGAAT-3 , and antisense, 5 -GTTGGCTCCTCTGTG-
TAACTG T-3 ; and Runx1 sense, 5 -TCGGCATGTCAGCCATGAG-
3 , and antisense 5 -TGGTGGGCGAGTTGCTATG-3 . Cycling parame-
ters were denaturation at 94 C for 15 s, annealing at 58 C (c-Kit at 60 C) for
15 s, and extension at 72 C for 30 s. The amplification proceeded for 36–38
cycles. PCR products were separated on an agarose gel and visualized by
ethidium bromide staining.
FACS analysis and cell sorting. Mouse CD34 KSL cells were purified
from BM of 2-mo-old mice. In brief, low-density cells were isolated on
1.086 g/ml Ficoll-Paque PLUS (GE Healthcare). The cells were stained
with an antibody cocktail consisting of biotinylated anti–Gr-1, –Mac-1,
-B220, -CD4, -CD8, and –Ter-119 mAbs (eBioscience). Lin  cells were
depleted with streptavidin-conjugated magnetic beads (M-280; Dynal). The
cells were further stained with FITC-conjugated anti-CD34, PE-conju-
gated anti–Sca-1, and allophycocyanin-conjugated anti–c-Kit antibodies
(BD Biosciences). Biotinylated antibodies were detected with streptavidin–
Texas red (Invitrogen). Four-color analysis and sorting were performed on a
FACSVantage (Becton Dickinson). To detect Endomucin expression, BM
mononuclear cells were first reacted with a mixture of purified antibodies
against lineage markers (Gr-1, Mac-1, CD4, CD8, B220, and TER119;
eBioscience), followed by reaction with anti–rat IgG microbeads (Miltenyi
Biotech). Magnetically labeled cells were then passed through an LD col-
umn (Miltenyi Biotech), and the flow-through cells were recovered as cells
depleted in populations bearing lineage markers. Cells depleted in such
populations were stained with biotinylated anti-Endomucin mAb (clone
V.7C7) (19), FITC-conjugated anti-CD34, allophycocyanin-conjugated
anti–c-Kit, and PE–Cy5.5-conjugated anti–Sca-1 (Caltag). A mixture of
antibodies against lineage markers was not included in this staining. Biotin-
ylated anti–mouse Endomucin mAb was detected with streptavidin–PE (BD
Biosciences). FACS analysis and cell sorting were performed on a FACS-
Vantage using CellQuest software (Becton Dickinson), a FACSAria using
FACSDiva software (Becton Dickinson), or a MoFlo using Summit soft-
ware (DakoCytomation).
Colony assay. Single cells were directly sorted into 96-well roundbottom
plates containing 150  l S-clone (Sanko Junyaku) supplemented with 10%
FCS (Sigma-Aldrich), 5   10 4 M 2-mercaptoethanol (Sigma-Aldrich), 10
ng/ml mouse IL-3, 10 ng/ml mouse stem cell factor (mSCF), 2 U/ml hu-
man erythropoietin (EPO), and 50 ng/ml human thrombopoietin (TPO;
PeproTech). After 14 d of culture in a humidified 5% CO2 atmosphere,
colonies were scored by light microscopical examination and were recov-
ered, cytospun onto slide glasses, and subjected to May-Gruenwald Giemsa
staining for morphological examination.
Competitive repopulation assays for adult donor cells. The Ly5 sys-
tem was adopted for competitive repopulation assay as previously described
(1). C57BL/6-Ly5.1 donor-derived test cells were collected by cell sorting
and injected intravenously together with 2   105 total BM competitor cells
from B6-Ly5.1   Ly5.2 F1 mice into 9.5-Gy irradiated B6-Ly5.2 mice. 6
mo after transplantation, peripheral blood cells of recipient mice were col-
lected and stained with biotinylated anti-Ly5.1 (eBioscience), FITC-conju-
gated anti-Ly5.2, allophycocyanin-conjugated anti–Gr-1, allophycocyanin-
conjugated anti–Mac-1, PE-conjugated anti-CD4, PE-conjugated anti-CD8
(BD Biosciences), PE–Cy7-conjugated anti-B220 (Caltag), and streptavidin–
Texas red. Percent chimerism was calculated as follows: total percent chi-
merism   donor-derived cells / (donor-derived cells   competitor-derived
cells)   100; and percent chimerism lineage   donor-derived lineage-posi-
tive cells / (donor-derived lineage-positive cells   competitor-derived lin-
eage-positive cells)   100. Mice that had  1% chimerism in each lineage
were considered to be multilineage reconstituted. Median and standard devi-
ation values were calculated among the reconstituted recipients.
Analyses of embryonic hematopoiesis. Fetuses were collected in ice-
cold PBS from C57BL/6 pregnant mice. Yolk sacs and AGM regions from
E10.5 fetuses and yolk sacs from E8.5 fetuses were collected separately. Sin-JEM VOL. 202, December 5, 2005 1491
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gle-cell suspensions were prepared by treating fetal tissues with 0.05% colla-
genase for 20–40 min at 37 C. Cells were stained with biotinylated anti-Endo-
mucin (V.7C7) and FITC-conjugated anti-CD41 or PE-conjugated anti-
CD45 (BD Biosciences). Cell fractions were recovered by cell sorting and
plated in triplicate on an OP-9 layer for co-culture assays. For colony assays,
sorted cells were suspended in  -MEM–based 1.2% methylcellulose (Sigma-
Aldrich), 30% FCS (Sigma-Aldrich), 1% BSA (Sigma-Aldrich), 10 4 M
2-mercaptoethanol (100 U/ml), 10 ng/ml mouse IL-3, 10 ng/ml mSCF, 2
U/ml EPO, and 50 ng/ml TPO. Numbers of EryP cells were determined at day
2–3 of culture. Numbers of CFU-Cs were determined at day 12 of culture.
A competitive adult BM repopulation assay was performed using the number
of purified AGM cells (B6-Ly5.2) indicated in the figures and 3   105 B6-
Ly5.1 competitor cells. 105 B6-Ly5.1 competitor cells were injected together
with AGM cells directly into the BM (intra-BM transplantation) of lethally
irradiated B6-Ly5.1 recipient mice. An additional 2   105 B6-Ly5.1 com-
petitor cells were injected intravenously. After 3 mo, peripheral blood cells
of recipient mice were collected and stained with biotinylated anti-Ly5.1,
FITC-conjugated anti-Ly5.2, allophycocyanin-conjugated anti–Gr-1, allo-
phycocyanin-conjugated anti–Mac-1, PE-conjugated anti-CD4, PE-conju-
gated anti-CD8, PE–Cy7-conjugated anti-B220, and streptavidin–Texas red.
Percent chimerism was calculated as in the previous section. Mice that had
 0.1% chimerism in each lineage were considered positive.
OP-9 co-culture. OP-9 cells (density of 40,000 cells/ well) were plated
on four-chamber culture slides (BD Biosciences) or on 24-well culture
plates 1 day before the initiation of co-culture. Sorted cells were placed
onto OP-9 layers in triplicate and were co-cultured in  -MEM supple-
mented with 10% FCS, 2 mM L-glutamine, 5   10 4 M 2-mercaptoetha-
nol (100 U/ml), 10 ng/ml mouse IL-3, 10 ng/ml mSCF, 2 U/ml EPO, and
50 ng/ml TPO. At day 2 of co-culture, the colonies growing were
counted. At day 6, single-cell suspensions were prepared and the hemato-
poietic cells were counted, using a hemocytometer (Erma), while excluding
OP-9 cells by their size and morphology.
Online supplemental material. Fig. S1 provides data for Endomucin
expression during hematopoietic development from ES cells. Fig. S2 pro-
vides data for Endomucin expression during fetal liver hematopoiesis. Table
S1 provides the list of SST-REX–selected clones. Supplemental Materials
and methods provides the methods for induction of hematopoiesis from ES
cells. Online supplemental material is available at http://www.jem.org/cgi/
content/full/jem.20051325/DC1.
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